Physician profile
Paul W Walker
NPI 1265633051
$2,986.09
in general payments reported to CMS, 2019-2025
33 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $87.42 · 2021: $483 · 2022: $404 · 2023: $921 · 2024: $276 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $388.89 | 2019-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $354.73 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $259.12 | 2019-2023 | Provenge |
| Janssen Biotech, INC. | $258.40 | 2019-2023 | |
| Antares Pharma, INC. | $236.67 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Procept Biorobotics Corporation | $208.09 | 2021-2024 | Aquabeam System, Aquabeam Robotic System |
| Blue Earth Diagnostics | $204.97 | 2019-2022 | |
| Axogen | $125.86 | 2025 | |
| Abbvie INC. | $100.97 | 2021-2024 | Botox |
| Bayer Healthcare Pharmaceuticals INC. | $98.32 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $86.65 | 2019-2023 | Aveed, Xiaflex |
| C. R. Bard, INC. & Subsidiaries | $84.29 | 2023 | Bard Urinary Drainage Bag |
| Progenics Pharmaceuticals, INC. | $70.14 | 2022-2023 | Pylarify |
| Myriad Genetic Laboratories, INC. | $51.85 | 2021-2023 | Prolaris |
| Urovant Sciences INC | $51.70 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $50.51 | 2023 | |
| Hollister Incorporated | $38.32 | 2021-2023 | Infyna Chic |
| Tolmar Pharmaceuticals, INC. | $38.30 | 2019 | |
| Rochester Medical Corporation | $37.70 | 2019-2020 | |
| Neotract INC. | $26.52 | 2019 | |
| Pfizer INC. | $25.83 | 2019 | |
| Merck Sharp & Dohme LLC | $21.38 | 2022 | |
| Agiliti Surgical, INC. | $19.65 | 2019 | |
| 180 Medical, INC. | $17.99 | 2019 | |
| Tolmar, INC. | $17.31 | 2023 | |
| Boston Scientific Corporation | $16.65 | 2023 | |
| Axonics, INC. | $16.16 | 2022 | |
| Myovant Sciences INC. | $14.75 | 2021 | |
| Halozyme INC | $14.66 | 2023 | |
| Urogen Pharma, INC. | $13.62 | 2021 | |
| Clarus Therapeutics INC. | $12.42 | 2021 | |
| Acerus Pharmaceuticals Corporation | $11.85 | 2021 | |
| Ethicon US, LLC | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.